Countries Australia

Delonix Bioworks Secures China IND Clearance For MenB Vaccine Candidate DX 104

 Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B...

 February 09, 2026 | News

Imagion Biosystems Files FDA IND For MagSense Molecular MRI Cancer Imaging Platform

Imagion Biosystems, Ltd. (ASX: IBX) announced that the company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Adminis...

 February 06, 2026 | News

Australian World First Paediatric mRNA Brain Cancer Trial Signals Expansion Opportunity For Canada And The United States

Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. -- Providence Ther...

 February 06, 2026 | News

Monash Innovation Labs And Agilent Technologies Australia Deepen Applied Research Partnership

Monash Innovation Labs and Agilent Technologies Australia have formalised a new partnership to embed advanced analytical instrumentation wit...

 February 03, 2026 | News

Kazia Therapeutics Advances First In Class Nuclear PD L1 Protein Degrader With Compelling Preclinical Evidence

 Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, announced co...

 February 02, 2026 | News

SK Bioscience Launches Global Phase1/2 Trial In Australia For Universal Sarbecovirus Vaccine GBP511

SK bioscience announced the initiation of a global Phase 1/2 clinical trial in Australia for GBP511, a vaccine candidate targeting the sarbecovirus subgenu...

 January 30, 2026 | News

Kazia Therapeutics Reports Encouraging Early Responses For Paxalisib Combination In Advanced Triple Negative Breast Cancer

Kazia Therapeutics provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemothe...

 January 29, 2026 | News

Telix Doses First US Patient In Phase Three BiPASS Prostate Cancer Imaging Trial

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix")  announces that the first patient in the United States (U.S.) has been dosed in BiPASS&...

 January 20, 2026 | News

Australia TGA Clears NMN As A Permissible Therapeutic Ingredient In Landmark Longevity Move

One of the most popular ingredients in the field of  longevity science globally, nicotinamide mononucleotide (NMN) has officially  been listed as...

 January 15, 2026 | News

Clover Advances Global First In Class Respiratory Vaccine Strategy With Phase Two Launch

- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candid...

 January 13, 2026 | News

Co Diagnostics Secures First Patent For Point Of Care PCR Platform In Australia

The Australian patent represents the first patent granted for the Company's new point-of-care testing platform  Co-Diagnostics, I...

 December 31, 2025 | News

Ferronova Raises $6 Million To Advance Nanoparticle Guided Cancer Surgery Technology

Australian company Ferronova has raised a further $6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solut...

 December 18, 2025 | News

Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA ...

 December 18, 2025 | News

Pixelgen Expands Asia Pacific Footprint With South Korea Distribution Agreement

- Pixelgen Technologies, Inc. and MDxK (Molecular Diagnostics Korea) Inc., part of DKSH Business Unit Technology, a leader in market expansion se...

 December 16, 2025 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close